US Stock Futures Recover as Iran Signals Progress in Peace Talks 
U.S.-Iran Diplomacy Helps Drive Gasoline Prices Down 15% From May Highs 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
South Korea’s KOSPI Rebounds as Samsung and SK Hynix Lead Tech Stock Recovery 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
US Dollar Hits One-Year High as Hawkish Fed Outlook Overshadows Middle East Developments 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Bessent Says U.S. Must Strengthen Supply Chains and Economic Security 
Novo Nordisk, a Danish pharmaceutical firm based in Bagsværd, Denmark, announced on Thursday, Aug. 10, that it will buy privately held the Canadian obesity drug manufacturer Inversago Pharma.
The company said the deal may be worth up to $1.08 billion. Novo Nordisk said there is no exact price yet as of this time because the determination will depend on whether Inversago Pharma is able to achieve certain development and target sales.
CNBC reported that the firms are looking to close the deal before 2023 ends. Novo Nordisk’s decision to acquire the Canadian company is a strategic move to further widen its weight loss portfolio.
The transaction also comes after its Wegovy prescription medication for adults with obesity and Ozempic weight loss injectibles’ popularity took off to great heights. The company is taking advantage of this achievement and aims to keep this momentum going by adding Inversago Pharma and its products into its own weight loss and obesity treatment offering lineup.
“The acquisition of Inversago Pharma will further strengthen our clinical development pipeline in obesity and related disorders,” Novo Nordisk’s executive vice president for development, Martin Holst Lange, commented in a press release. “This promising class of medicine pioneered by the Inversago team could lead to life-changing new treatment options for those living with a serious chronic disease and, in particular, may offer alternative or complementary solutions for people living with obesity.”
Finally, François Ravenelle, Inversago Pharma’s chief executive officer, also said they “are delighted to join forces with a global leader in the obesity and metabolic disorder space. It added that they “believe this combination will help unlock the full medical potential of their CB1 blockers and may one day expand treatment options for people living with metabolic syndrome, obesity, and related complications.”
Photo by: Novo Nordisk Media Library
